Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health (Nasdaq: GH) announced the approval of equity awards for new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The compensation package includes:
- 110,681 restricted stock units (RSUs) granted to 102 new non-executive employees
- One non-qualified stock option award to purchase 22,091 shares granted to one new employee
The stock options have an exercise price of $42.44 per share, matching Guardant's closing price on Nasdaq on February 24, 2025. The RSUs vest annually over three years, while stock options vest one-third after one year and monthly thereafter over 24 months, subject to continued employment. These grants were approved on February 11, 2025, with a grant date of February 24, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Guardant Health (Nasdaq: GH) ha annunciato l'approvazione di premi azionari per nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivazione all'Occupazione 2023. Il pacchetto retributivo include:
- 110.681 unità azionarie vincolate (RSU) assegnate a 102 nuovi dipendenti non esecutivi
- Un premio di opzione su azioni non qualificate per l'acquisto di 22.091 azioni assegnato a un nuovo dipendente
Le opzioni su azioni hanno un prezzo di esercizio di 42,44 dollari per azione, corrispondente al prezzo di chiusura di Guardant su Nasdaq il 24 febbraio 2025. Le RSU maturano annualmente per tre anni, mentre le opzioni su azioni maturano un terzo dopo un anno e mensilmente successivamente per 24 mesi, soggette a un impiego continuato. Questi premi sono stati approvati l'11 febbraio 2025, con una data di assegnazione del 24 febbraio 2025, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Guardant Health (Nasdaq: GH) anunció la aprobación de premios en acciones para nuevos empleados no ejecutivos bajo su Plan de Incentivo de Empleo 2023. El paquete de compensación incluye:
- 110,681 unidades de acciones restringidas (RSUs) otorgadas a 102 nuevos empleados no ejecutivos
- Un premio de opción sobre acciones no calificadas para comprar 22,091 acciones otorgado a un nuevo empleado
Las opciones sobre acciones tienen un precio de ejercicio de $42.44 por acción, coincidiendo con el precio de cierre de Guardant en Nasdaq el 24 de febrero de 2025. Las RSUs se consolidan anualmente durante tres años, mientras que las opciones sobre acciones se consolidan un tercio después de un año y mensualmente a partir de entonces durante 24 meses, sujeto a empleo continuo. Estos premios fueron aprobados el 11 de febrero de 2025, con una fecha de concesión del 24 de febrero de 2025, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Guardant Health (Nasdaq: GH)는 2023년 고용 유인 인센티브 상여 계획에 따라 신규 비임원 직원에 대한 주식 보상 승인을 발표했습니다. 보상 패키지는 다음을 포함합니다:
- 102명의 신규 비임원 직원에게 부여된 110,681개의 제한 주식 단위(RSU)
- 한 명의 신규 직원에게 부여된 22,091주를 구매할 수 있는 비자격 주식 옵션 상여
주식 옵션의 행사 가격은 $42.44로, 2025년 2월 24일 Nasdaq에서의 Guardant의 종가와 일치합니다. RSU는 3년에 걸쳐 매년 배분되며, 주식 옵션은 1년 후 1/3이 배분되고 이후 24개월 동안 매월 배분됩니다. 이러한 보상은 2025년 2월 11일에 승인되었으며, 2025년 2월 24일을 부여일로 하여 Nasdaq 상장 규칙 5635(c)(4)에 따라 진행되었습니다.
Guardant Health (Nasdaq: GH) a annoncé l'approbation de récompenses en actions pour de nouveaux employés non exécutifs dans le cadre de son Plan d'Incentive à l'Emploi 2023. Le package de compensation comprend :
- 110 681 unités d'actions restreintes (RSU) accordées à 102 nouveaux employés non exécutifs
- Une récompense d'option d'achat d'actions non qualifiées pour l'achat de 22 091 actions accordée à un nouvel employé
Les options sur actions ont un prix d'exercice de 42,44 $ par action, correspondant au prix de clôture de Guardant sur Nasdaq le 24 février 2025. Les RSU se libèrent annuellement sur trois ans, tandis que les options sur actions se libèrent un tiers après un an et mensuellement par la suite sur 24 mois, sous réserve d'un emploi continu. Ces récompenses ont été approuvées le 11 février 2025, avec une date d'attribution du 24 février 2025, conformément à la règle d'inscription Nasdaq 5635(c)(4).
Guardant Health (Nasdaq: GH) hat die Genehmigung von Aktienprämien für neue nicht-executive Mitarbeiter im Rahmen seines 2023 Employment Inducement Incentive Award Plans bekannt gegeben. Das Vergütungspaket umfasst:
- 110.681 Restricted Stock Units (RSUs), die an 102 neue nicht-executive Mitarbeiter vergeben wurden
- Eine nicht qualifizierte Aktienoptionsprämie zum Kauf von 22.091 Aktien, die an einen neuen Mitarbeiter vergeben wurde
Die Aktienoptionen haben einen Ausübungspreis von 42,44 $ pro Aktie, was dem Schlusskurs von Guardant an der Nasdaq am 24. Februar 2025 entspricht. Die RSUs werden über drei Jahre jährlich fällig, während die Aktienoptionen ein Drittel nach einem Jahr und dann monatlich über 24 Monate fällig werden, vorausgesetzt, das Arbeitsverhältnis wird fortgesetzt. Diese Zuwendungen wurden am 11. Februar 2025 genehmigt, mit einem Zuwendungsdatum vom 24. Februar 2025, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Employee expansion with 103 new hires indicates company growth
- Structured equity compensation plan helps attract new talent
- Potential dilution of existing shareholders from new equity grants
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award vest on an annual basis on the anniversary of the vesting commencement date, subject to each employee’s continued employment with Guardant as of each such vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
All stock options have an exercise price of
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250228155474/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711
Source: Guardant Health, Inc.
FAQ
How many RSUs did Guardant Health (GH) grant to new employees in February 2025?
What is the vesting schedule for Guardant Health's (GH) February 2025 RSU grants?
What was the exercise price for Guardant Health's (GH) stock options granted in February 2025?
How do the stock options vest in Guardant Health's (GH) February 2025 inducement grants?
